Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.51 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.51 |
| ▸ | MAOB | P27338 | 5/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.50 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | HPD | P32754 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2959082 | 0.97 | CYP4F2 (0.51) | CYP4F2CYP4A11MAOBNR4A2ADAM17 | |
| SCHEMBL9217663 | 0.87 | ALOX5 (0.61) | ALOX5 | |
| SCHEMBL6042553 | 0.84 | OPRL1 (0.66) | — | |
| SCHEMBL22091686 | 0.84 | OPRL1 (0.58) | CYP4F2CYP4A11MAOBADAM17 | |
| SCHEMBL16553890 | 0.83 | LMNA (0.56) | MAOBNR4A2BCHEMAOA | |
| SCHEMBL2587746 | 0.83 | ALDH1A1 (0.50) | CYP4F2CYP4A11MAOBNR4A2ADAM17 | |
| SCHEMBL9352651 | 0.82 | ALOX5 (0.70) | CYP4F2CYP4A11ADAM17ALOX5 | |
| Ethane SCHEMBL11640556 | 0.80 | MAOB (0.46) | CYP4F2CYP4A11MAOBNR4A2ADAM17 | |
| SCHEMBL8317190 | 0.80 | NOS2 (0.58) | CYP4F2CYP4A11NR4A2 | |
| SCHEMBL1660385 | 0.80 | KMT2A (0.46) | CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | PFIZER INC | 2004-11-18 | — | — | US | disclosed |
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | PFIZER INC | 2004-11-18 | — | — | US | disclosed |
| EP-0958282-B1 | 2-AMINO-6-(2-SUBSTITUTED-4-PHENOXY)-SUBSTITUTED-PYRIDINES | PFIZER PROD INC (US) | 2004-07-21 | — | — | EP | disclosed |
| US-20030162765-A1 | Use in treatment and prevention of central nervous system and other disorders | PFIZER INC. | 2003-08-28 | — | — | US | disclosed |
| US-20010007873-A1 | Compounds such as 4-(6-amino-pyridin-2-yl)-3-methoxyphenol as nitric oxide synthase inhibitors used to treat central nervous system disorders, inflammatory disorders, septic shock, etc... | PFIZER INC. | 2001-07-12 | — | — | US | disclosed |
| EP-0958282-A1 | 2-AMINO-6-(2-SUBSTITUTED-4-PHENOXY)-SUBSTITUTED-PYRIDINES | Pfizer Products Inc. (US) | 1999-11-24 | — | — | EP | disclosed |
| WO-1998034919-A1 | 2-AMINO-6-(2-SUBSTITUTED-4-PHENOXY)-SUBSTITUTED-PYRIDINES | PFIZER PRODUCTS INC. (US) | 1998-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010007873-A1 | Compounds such as 4-(6-amino-pyridin-2-yl)-3-methoxyphenol as nitric oxide synthase inhibitors used to treat central nervous system disorders, inflammatory disorders, septic shock, etc... | NOS1, PTGS1, NOS2 | CYP4F2 216/4885CYP4A11 111/4885MAOB 255/4885 |
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | NOS1, NOS3, NPBWR1 | CYP4F2 2528/4885CYP4A11 325/4885MAOB 135/4885 |
| US-20030162765-A1 | Use in treatment and prevention of central nervous system and other disorders | GRIN2C, GRIN2A, CNR2 | CYP4F2 388/4885CYP4A11 572/4885MAOB 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.